A Phase 2 Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Virus-Like Particle Vaccine IVX-A12 in Adults ≥60 Years of Age
The Journal of Infectious Diseases · 03.11.2026
DOI: 10.1093/infdis/jiag531 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.11.2026. Verfasst von Temitope Oyedele und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Icosavax, AstraZeneca.
Abstract (Originalsprache)
Background
Older adults (≥60 years) are susceptible to severe outcomes from infection with respiratory syncytial virus (RSV) or human metapneumovirus (hMPV). IVX-A12 is an investigational vaccine that uses virus-like particles (VLPs) to elicit an immune response against RSV and hMPV.
Methods
This phase 2 trial (NCT06481579) randomized (1:1) adults ≥60 years of age to receive a single dose of IVX-A12 (150 µg RSV/150 µg hMPV) or the licensed RSV vaccine RSVPreF3 120 µg with AS01E adjuvant. Safety and immunogenicity were evaluated through 180 days post-vaccination.
Results
Overall, 143 participants received IVX-A12 (n = 71) or RSVPreF3 (n = 72). Solicited adverse reactions were reported through 7 days post-vaccination (IVX-A12, 25 [35.2%]; RSVPreF3, 36 [50.0%]). Unsolicited adverse events (AEs) were collected through day 29 (IVX-A12, 5 [7.0%]; RSVPreF3, 11 [15.3%]). Serious AEs (IVX-A12, 2 [2.8%]; RSVPreF3, 1 [1.4%]) and medically attended AEs (IVX-A12, 1 [1.4%]; RSVPreF3, 9 [12.5%]) were documented through day 181. There were no AEs of special interest or AEs leading to study discontinuation. At day 29, IVX-A12 and RSVPreF3 administration increased RSV A neutralizing antibody (nAb) levels with geometric mean fold rise (GMFR) of 3.4 and 6.5, and RSV B nAb levels with GMFR of 2.9 and 5.4, respectively. IVX-A12, but not RSVPreF3, also increased hMPV A (GMFR 3.0) and hMPV B (GMFR 2.9) nAb levels.
Conclusions
IVX-A12 and RSVPreF3 were well tolerated and elicited nAb responses against their targeted pathogens. Given the neutralizing antibody response following IVX-A12, further investigation of an RSV-hMPV VLP combination vaccine is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Development, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
- Peninsula Research Associates, Rolling Hills Estates, CA, USA.
- Coastal Carolina Research Center, North Charleston, SC, USA.
- Cenexel RCA, Hollywood, FL, USA.
- Icosavax, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Seattle, WA, USA.
- Biometrics, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
ORCID-Profile: Lawrence D Sher, Lee-Jah Chang
Förderung
- Icosavax
- AstraZeneca
Zitieren
APA
Oyedele, T., Sher, L. D., Morales, K., Shapiro, C., Adams, E., MacDonald, M., Wen, J., Pura, J. A., Shoemaker, K., Price, J., Brown, A. S., Aksyuk, A. A., Cohen, T. S., & Chang, L. J. (2026). A Phase 2 Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Virus-Like Particle Vaccine IVX-A12 in Adults ≥60 Years of Age. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag531
Vancouver
Oyedele T, Sher LD, Morales K, Shapiro C, Adams E, MacDonald M, et al. A Phase 2 Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Virus-Like Particle Vaccine IVX-A12 in Adults ≥60 Years of Age. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag531
BibTeX
@article{Oyedele2026,
author = {Oyedele, Temitope and Sher, Lawrence D and Morales, Kelly and Shapiro, Craig and Adams, Elizabeth and MacDonald, Margaret and Wen, Judy and Pura, John A and Shoemaker, Kathryn and Price, Jennifer and Brown, Ami Shah and Aksyuk, Anastasia A and Cohen, Taylor S and Chang, Lee-Jah},
title = {A Phase 2 Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Virus-Like Particle Vaccine IVX-A12 in Adults ≥60 Years of Age},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag531}
}
EUVIMED